RxDoctor Payments DataLook up a doctor →

Monty Morales, MD

Cardiovascular Disease · Tucson, AZNPI 1043298656

Payments from drug & device makers

$39,332in general payments, 2019–2025

Across 821 payments — averaging $47.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$14K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
  • Boston Scientific$3K
  • Abbott$3K
  • Abiomed$1K
  • Acutus Medical, Inc.$1K
  • plus $8K from 36 others

What the payments were for

  • Consulting fees$5001%
  • Speaking & faculty fees$20,67553%
  • Food & beverage$18,15746%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,332 in reported general payments places this provider in the 85th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$788,703
Medicare patients
1,495
Services billed
6,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,198$1,207,081
XareltoRivaroxaban277$335,894
EntrestoSacubitril/Valsartan290$292,825
Repatha SureclickEvolocumab242$195,470
JardianceEmpagliflozin38$51,570
MultaqDronedarone Hcl22$36,771
Praluent PenAlirocumab35$30,479
BrilintaTicagrelor25$16,591
Flecainide Acetate453$14,852
Ranolazine ErRanolazine82$10,267
Metoprolol Succinate733$9,746
Repatha SyringeEvolocumab18$8,198
Atorvastatin Calcium593$6,192
Carvedilol704$6,164
Ezetimibe219$6,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$427$1,207,0811,198 claims
Johnson & JohnsonXarelto$1,051$335,894277 claims
NovartisEntresto$798$292,825290 claims
Boehringer IngelheimJardiance$461$51,57038 claims
Sanofi-aventis U.S. LLCMultaq$58$36,77122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →